Clinical Cancer Research CR Helping Patients Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bui, M. H. T.
Right arrow Articles by Belldegrun, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bui, M. H. T.
Right arrow Articles by Belldegrun, A. S.
Clinical Cancer Research Vol. 9, 802-811, February 2003
© 2003 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma

Implications for Prognosis and Therapy

Matthew H. T. Bui1, David Seligson1, Ken-ryu Han, Allan J. Pantuck, Frederick J. Dorey, Yunda Huang, Steve Horvath, Bradley C. Leibovich, Shefali Chopra, Shu-Yuan Liao, Eric Stanbridge, Michael I. Lerman, Aarno Palotie, Robert A. Figlin and Arie S. Belldegrun2

Departments of Urology [M. H. T. B., K. H., A. J. P., B. C. L., R. A. F., A. S. B.], Pathology and Laboratory Medicine [D. S., S. C.], Biostatistics and Human Genetics [F. J. D., Y. H., S. H.], Surgery, Medicine, University of California, Los Angeles, California 90095-1738 [M. H. T. B., D. S., K. H., A. J. P., F. J. D., Y. H., S. H., B. C. L., S. C., A. P., R. A. F., A. S. B.]; Department of Microbiology and Molecular Genetics, University of California, Irvine, California [S-Y. L., E. S.]; and National Cancer Institute, Bethesda, Maryland [M. I. L.]

Purpose: Metastatic renal cell carcinoma (RCC) has a poor prognosis and an unpredictable course. To date, there are no molecular markers which can reliably predict RCC outcome. We investigated whether a novel kidney cancer marker, carbonic anhydrase IX (CAIX), is associated with progression and survival.

Experimental Design: Immunohistochemical analysis using a CAIX monoclonal antibody was performed on tissue microarrays constructed from paraffin-embedded specimens from patients (N = 321) treated by nephrectomy for clear cell RCC. CAIX staining was correlated with response to treatment, clinical factors, pathologic features, and survival.

Results: CAIX staining was present in 94% of clear cell RCCs. Survival tree analysis determined that a cutoff of 85% CAIX staining provided the most accurate prediction of survival. Low CAIX (<=85%) staining was an independent poor prognostic factor for survival for patients with metastatic RCC, with a hazard ratio of 3.10 (P < 0.001). CAIX significantly substratified patients with metastatic disease when analyzed by T stage, Fuhrman grade, nodal involvement, and performance status (P < 0.001, = 0.001, = 0.009, = 0.005, respectively). For patients with nonmetastatic RCC and at high risk for progression, low CAIX predicted a worse outcome similar to patients with metastatic disease (P = 0.058). Overall expression of CAIX decreased with development of metastasis; as demonstrated by the lower CAIX staining levels in metastatic lesions relative to matched primary tumor specimens (P = 0.036).

Conclusions: On the basis of our data, CAIX is the most significant molecular marker described in kidney cancer to date. Decreased CAIX levels are independently associated with poor survival in advanced RCC. CAIX reflects significant changes in tumor biology, which should be used to predict clinical outcome and identify high-risk patients in need for adjuvant immunotherapy and CAIX-targeted therapies.




This article has been cited by other articles:


Home page
 JCOHome page
B. I. Rini
Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient
J. Clin. Oncol., July 1, 2009; 27(19): 3225 - 3234.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. Klatte, D. B. Seligson, J. LaRochelle, B. Shuch, J. W. Said, S. B. Riggs, N. Zomorodian, F. F. Kabbinavar, A. J. Pantuck, and A. S. Belldegrun
Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy
Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 894 - 900.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Klatte, P. N. Rao, M. de Martino, J. LaRochelle, B. Shuch, N. Zomorodian, J. Said, F. F. Kabbinavar, A. S. Belldegrun, and A. J. Pantuck
Cytogenetic Profile Predicts Prognosis of Patients With Clear Cell Renal Cell Carcinoma
J. Clin. Oncol., February 10, 2009; 27(5): 746 - 753.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Kim, E. Jonasch, A. Alexander, J. D. Short, S. Cai, S. Wen, D. Tsavachidou, P. Tamboli, B. A. Czerniak, K. A. Do, et al.
Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma
Clin. Cancer Res., January 1, 2009; 15(1): 81 - 90.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Wang, X.-Y. Wang, J. R. Subjeck, and H. L. Kim
Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant
Mol. Cancer Ther., December 1, 2008; 7(12): 3867 - 3877.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Greiner, L. Bullinger, B.-a. Guinn, H. Dohner, and M. Schmitt
Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells
Clin. Cancer Res., November 15, 2008; 14(22): 7161 - 7166.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. H. Brouwers, P. F.A. Mulders, and W. J.G. Oyen
Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma and Normal Tissues: Experiences From (Radio) Immunotherapy
J. Clin. Oncol., August 1, 2008; 26(22): 3808 - 3809.
[Full Text] [PDF]

Home page
 JCOHome page
P. Skapa, L. Hyrsl, J. Zavada, J. Soukup, and J. Zamecnik
Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinomas Negatively Correlates With the Proportion of the Granular Cell Component
J. Clin. Oncol., August 1, 2008; 26(22): 3809 - 3811.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Skrzypski, E. Jassem, M. Taron, J. J. Sanchez, P. Mendez, W. Rzyman, G. Gulida, D. Raz, D. Jablons, M. Provencio, et al.
Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung
Clin. Cancer Res., August 1, 2008; 14(15): 4794 - 4799.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. Pantuck, T. Klatte, D. Seligson, M. Atkins, and A. Belldegrun
Carbonic Anhydrase IX As a Predictive Biomarker for Clear Cell Renal Cell Carcinoma
J. Clin. Oncol., June 20, 2008; 26(18): 3105 - 3107.
[Full Text] [PDF]

Home page
 JCOHome page
B. C. Leibovich, Y. Sheinin, C. M. Lohse, R. H. Thompson, J. C. Cheville, J. Zavada, and E. D. Kwon
In Reply
J. Clin. Oncol., June 20, 2008; 26(18): 3107 - 3109.
[Full Text] [PDF]

Home page
 NEJMHome page
M. D. Michaelson, O. Iliopoulos, D. F. McDermott, F. J. McGovern, M. G. Harisinghani, and E. Oliva
Case 17-2008 -- A 63-Year-Old Man with Metastatic Renal-Cell Carcinoma
N. Engl. J. Med., May 29, 2008; 358(22): 2389 - 2396.
[Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
W. K. Rathmell, W. M. Stadler, and B. I. Rini
Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 192 - 198.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Klatte, D. B. Seligson, S. B. Riggs, J. T. Leppert, M. K. Berkman, M. D. Kleid, H. Yu, F. F. Kabbinavar, A. J. Pantuck, and A. S. Belldegrun
Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma
Clin. Cancer Res., December 15, 2007; 13(24): 7388 - 7393.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. C. Leibovich, Y. Sheinin, C. M. Lohse, R. H. Thompson, J. C. Cheville, J. Zavada, and E. D. Kwon
Carbonic Anhydrase IX Is Not an Independent Predictor of Outcome for Patients With Clear Cell Renal Cell Carcinoma
J. Clin. Oncol., October 20, 2007; 25(30): 4757 - 4764.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. M. Niemela, P. Hynninen, J.-P. Mecklin, T. Kuopio, A. Kokko, L. Aaltonen, A.-K. Parkkila, S. Pastorekova, J. Pastorek, A. Waheed, et al.
Carbonic Anhydrase IX Is Highly Expressed in Hereditary Nonpolyposis Colorectal Cancer
Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1760 - 1766.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
J. A. Garcia and B. I. Rini
Recent Progress in the Management of Advanced Renal Cell Carcinoma
CA Cancer J Clin, March 1, 2007; 57(2): 112 - 125.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Choueiri, B. Rini, J. Garcia, R. Baz, R. Abou-Jawde, S. Thakkar, P Elson, T. Mekhail, M Zhou, and R. Bukowski
Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma
Ann. Onc., February 1, 2007; 18(2): 249 - 255.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. Lam, A. J. Pantuck, A. S. Belldegrun, and R. A. Figlin
Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials
Clin. Cancer Res., January 15, 2007; 13(2): 703s - 708s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. F. McDermott
Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma
Clin. Cancer Res., January 15, 2007; 13(2): 716s - 720s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. I. Rini and W.K. Rathmell
Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma
Clin. Cancer Res., January 15, 2007; 13(2): 741s - 746s.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Greiner, M. Schmitt, L. Li, K. Giannopoulos, K. Bosch, A. Schmitt, K. Dohner, R. F. Schlenk, J. R. Pollack, H. Dohner, et al.
Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches
Blood, December 15, 2006; 108(13): 4109 - 4117.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. Lam, A. Breda, A. S. Belldegrun, and R. A. Figlin
Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma
J. Clin. Oncol., December 10, 2006; 24(35): 5565 - 5575.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Parton, M. Gore, and T. Eisen
Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer
J. Clin. Oncol., December 10, 2006; 24(35): 5584 - 5592.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. A. Varker, S. V. Kondadasula, M. R. Go, G. B. Lesinski, R. Ghosh-Berkebile, A. Lehman, J. P. Monk, T. Olencki, K. Kendra, and W. E. Carson III
Multiparametric Flow Cytometric Analysis of Signal Transducer and Activator of Transcription 5 Phosphorylation in Immune Cell Subsets In vitro and following Interleukin-2 Immunotherapy.
Clin. Cancer Res., October 1, 2006; 12(19): 5850 - 5858.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Schoffski, H. Dumez, P. Clement, A. Hoeben, H. Prenen, P. Wolter, S. Joniau, T. Roskams, and H. Van Poppel
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review
Ann. Onc., August 1, 2006; 17(8): 1185 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. Grosch, T. J. Maier, S. Schiffmann, and G. Geisslinger
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
J Natl Cancer Inst, June 7, 2006; 98(11): 736 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Uemura, K. Fujimoto, M. Tanaka, M. Yoshikawa, Y. Hirao, S. Uejima, K. Yoshikawa, and K. Itoh
A Phase I Trial of Vaccination of CA9-Derived Peptides for HLA-A24-Positive Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma.
Clin. Cancer Res., March 15, 2006; 12(6): 1768 - 1775.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. H. Frey, G. Lummen, T. Jager, K.-H. Jockel, K. W. Schmid, H. Rubben, N. Muller, W. Siffert, and A. Eisenhardt
The GNAS1 T393C Polymorphism Predicts Survival in Patients with Clear Cell Renal Cell Carcinoma
Clin. Cancer Res., February 1, 2006; 12(3): 759 - 763.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. H. Brouwers, O. C. Boerman, W. J.G. Oyen, and M. B. Atkins
In vivo Molecular Prediction of Carbonic Anhydrase IX-G250MN Expression on Immunotherapy Outcome in Renal Cancer
Clin. Cancer Res., December 15, 2005; 11(24): 8886 - 8886.
[Full Text] [PDF]

Home page
 NEJMHome page
H. T. Cohen and F. J. McGovern
Renal-Cell Carcinoma
N. Engl. J. Med., December 8, 2005; 353(23): 2477 - 2490.
[Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
R. R. Raval, K. W. Lau, M. G. B. Tran, H. M. Sowter, S. J. Mandriota, J.-L. Li, C. W. Pugh, P. H. Maxwell, A. L. Harris, and P. J. Ratcliffe
Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma
Mol. Cell. Biol., July 1, 2005; 25(13): 5675 - 5686.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. C. Panelli, E. Wang, and F. M. Marincola
The Pathway to Biomarker Discovery: Carbonic Anhydrase IX and the Prediction of Immune Responsiveness
Clin. Cancer Res., May 15, 2005; 11(10): 3601 - 3603.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Atkins, M. Regan, D. McDermott, J. Mier, E. Stanbridge, A. Youmans, P. Febbo, M. Upton, M. Lechpammer, and S. Signoretti
Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer
Clin. Cancer Res., May 15, 2005; 11(10): 3714 - 3721.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. F. McDermott, M. M. Regan, J. I. Clark, L. E. Flaherty, G. R. Weiss, T. F. Logan, J. M. Kirkwood, M. S. Gordon, J. A. Sosman, M. S. Ernstoff, et al.
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol., January 1, 2005; 23(1): 133 - 141.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. J. Kim, Z. N. Rabbani, R. T. Vollmer, E.-G. Schreiber, E. Oosterwijk, M. W. Dewhirst, Z. Vujaskovic, and M. J. Kelley
Carbonic Anhydrase IX in Early-Stage Non-Small Cell Lung Cancer
Clin. Cancer Res., December 1, 2004; 10(23): 7925 - 7933.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Wang, R. Lichtenfels, J. Bukur, Y. Ngalame, M. C. Panelli, B. Seliger, and F. M. Marincola
Ontogeny and Oncogenesis Balance the Transcriptional Profile of Renal Cell Cancer
Cancer Res., October 15, 2004; 64(20): 7279 - 7287.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. Lam, A. S. Belldegrun, and R. A. Figlin
Tissue Array-Based Predictions of Pathobiology, Prognosis, and Response to Treatment for Renal Cell Carcinoma Therapy
Clin. Cancer Res., September 15, 2004; 10(18): 6304S - 6309S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. B. Atkins, M. Regan, and D. McDermott
Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma
Clin. Cancer Res., September 15, 2004; 10(18): 6342S - 6346S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. L. Kim, D. Seligson, X. Liu, N. Janzen, M. H. T. Bui, H. Yu, T. Shi, R. A. Figlin, S. Horvath, and A. S. Belldegrun
Using Protein Expressions to Predict Survival in Clear Cell Renal Carcinoma
Clin. Cancer Res., August 15, 2004; 10(16): 5464 - 5471.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
B. D. Curti
Renal Cell Carcinoma
JAMA, July 7, 2004; 292(1): 97 - 100.
[Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
M. Kaluzova, S. Kaluz, M. I. Lerman, and E. J. Stanbridge
DNA Damage Is a Prerequisite for p53-Mediated Proteasomal Degradation of HIF-1{alpha} in Hypoxic Cells and Downregulation of the Hypoxia Marker Carbonic Anhydrase IX
Mol. Cell. Biol., July 1, 2004; 24(13): 5757 - 5766.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Maseide, R. A. Kandel, R. S. Bell, C. N. Catton, B. O'Sullivan, J. S. Wunder, M. Pintilie, D. Hedley, and R. P. Hill
Carbonic Anhydrase IX as a Marker for Poor Prognosis in Soft Tissue Sarcoma
Clin. Cancer Res., July 1, 2004; 10(13): 4464 - 4471.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
G. Hopfl, O. Ogunshola, and M. Gassmann
HIFs and tumors--causes and consequences
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2004; 286(4): R608 - R623.
[Abstract] [Full Text] [PDF]

Home page
 Recent Prog Horm ResHome page
M. L. Wahl, T. L. Moser, and S. V. Pizzo
Angiostatin and Anti-angiogenic Therapy in Human Disease
Recent Prog. Horm. Res., January 1, 2004; 59(1): 73 - 104.
[Abstract] [Full Text]

Home page
 J. Am. Soc. Nephrol.Home page
J. A. Sosman
Targeting of the VHL-Hypoxia-Inducible Factor-Hypoxia-Induced Gene Pathway for Renal Cell Carcinoma Therapy
J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2695 - 2702.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. J. Pantuck, G. Zeng, A. S. Belldegrun, and R. A. Figlin
Pathobiology, Prognosis, and Targeted Therapy for Renal Cell Carcinoma: Exploiting the Hypoxia-Induced Pathway
Clin. Cancer Res., October 15, 2003; 9(13): 4641 - 4652.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Zisman, A. J. Pantuck, M. H. T. Bui, J. W. Said, R. R. Caliliw, N. Rao, P. Shintaku, F. Berger, S. S. Gambhir, and A. S. Belldegrun
LABAZ1: A Metastatic Tumor Model for Renal Cell Carcinoma Expressing the Carbonic Anhydrase Type 9 Tumor Antigen
Cancer Res., August 15, 2003; 63(16): 4952 - 4959.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Hernandez, M. H. T. Bui, K.-r. Han, H. Mukouyama, D. G. Freitas, D. Nguyen, R. Caliliw, P. I. Shintaku, S. H. Paik, C.-L. Tso, et al.
Novel Kidney Cancer Immunotherapy Based on the Granulocyte- Macrophage Colony-stimulating Factor and Carbonic Anhydrase IX Fusion Gene
Clin. Cancer Res., May 1, 2003; 9(5): 1906 - 1916.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.